Author

James Kulp

Observed name: James K. Kulp

Observed institution: Coatesville Veterans Affairs Medical Center

OpenAlex ID: A5084065422

Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles

2010 · Neil Swanson, William Abramovits, et al. · Journal of the American Academy of Dermatology · 161

A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses.

2010 · Joseph L Jorizzo, Orit Markowitz, et al. · PubMed · 47

Strain differences in convulsive response to the excitotoxin kainic acid

1991 · Gregory T. Golden, George G. Smith, et al. · Neuroreport · 39

Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream.

2011 · C William Hanke, Neil Swanson, et al. · PubMed · 36

Pharmacokinetics of imiquimod 3.75% cream applied daily for 3 weeks to actinic keratoses on the face and/or balding scalp

2010 · James Kulp, Sharon Levy, et al. · Archives of Dermatological Research · 17

Pharmacokinetics of Daily Self‐Application of Imiquimod 3.75% Cream in Adult Patients With External Anogenital Warts

2012 · Jason Wu, Robert Feldman, et al. · The Journal of Clinical Pharmacology · 8

Safety and Efficacy of Multiple 16-week Courses of Topical Imiquimod for the Treatment of Large Areas of Skin Involved with Actinic Keratoses.

2009 · James Q Del Rosso, Howard Sofen, et al. · PubMed · 7

Works count: 7

Citation count: 315

H-index: 7

I10-index: 5